
    
      This is a multicenter, randomized, open label exploratory study, conducted in the US and
      Canada, evaluating the efficacy and safety of enzalutamide for extension of time to prostate
      cancer progression (pathological or therapeutic) in patients with clinically localized,
      histologically proven prostate cancer that is categorized as low risk or intermediate risk
      and who are under AS.
    
  